TDM does not improve treatment efficacy during Remicade therapy for inflammatory diseases

TDM does not improve treatment efficacy during Remicade therapy for inflammatory diseases

Proactive therapeutic drug monitoring vs. standard therapy did not significantly improve clinical remission rates over 30 weeks in patients with immune-mediated inflammatory diseases initiating Remicade therapy, according to study results.“The findings do not support routine use of therapeutic drug monitoring during infliximab induction for improving disease remission rates,” Silje Watterdal Syversen, MD, PhD, from the division of rheumatology and research at Diakonhjemmet Hospital in Oslo, Norway, and colleagues wrote.Syversen and colleagues conducted a randomized,Read More

Share on facebook
Share on twitter
Share on linkedin